Business ❯ Pharmaceuticals ❯ Acquisitions ❯ Merck & Co.

Cidara Therapeutics

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Regulatory uncertainty now determines whether the candidate advances to U.S. authorization.

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug